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Background: High plasma concentrations of the vitamin E-binding protein afamin have been previously shown to
be associated with insulin resistance and metabolic syndrome. We set out to determine whether the concentration
of afamin in the serum of women with polycystic ovarian syndrome (PCOS) is elevated in relation to the presence
and severity of insulin resistance (IR).
Methods: This cross-sectional study looked at 53 patients with PCOS and 49 non-PCOS patients. IR was diagnosed
as a HOMA Index >2.4 and confirmed with a three-hour glucose tolerance test. Serum concentrations of afamin
were determined using enzyme-linked immunosorbent assay (ELISA). Clinical characteristics, hormone and metabolic
parameters were correlated to afamin concentrations.
Results: Serum concentrations of afamin did not differ between women with PCOS and controls. When separated
according to the presence of IR a significant difference in median afamin levels was seen between PCOS with IR and
PCOS without IR (73.06+/−27.36 mg/L and 64.25+/−17.41 mg/L, p = 0.033). No difference in afamin levels was detected
when comparing the few controls with IR and the controls without IR (76.20+/−27.96 mg/L and 60.44+/−21.03 mg/L,
p = 0.235). On univariate analyses, afamin serum concentrations significantly correlated with BMI, triglycerides, HOMA
Index, and AUC–Insulin. On multivariate linear regression analysis, only triglyceride concentration was seen to be an
independent predictor of afamin. Subjects with metabolic syndrome had higher median afamin concentrations than
did those without metabolic syndrome (77.43+/−28.60 mg/L and 65.08+/−18.03 mg/L, p = 0.010).
Conclusions: Elevated afamin concentrations are associated with the presence of metabolic syndrome in young
women and may potentially serve as an independent predictor for the development of metabolic syndrome in at-risk
women, especially those with IR.
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Polycystic ovary syndrome (PCOS) was first described in
1935 by Stein and Leventhal in patients with amenor-
rhoea, hirsutism, obesity and histological evidence of
polycystic ovaries [1]. PCOS is a heterogeneous syn-
drome of unclear etiology with a prevalence of up to
20%, making it the most frequent endocrine disorder in
women of reproductive age [2,3]. There exist, however,* Correspondence: hans.dieplinger@i-med.ac.at
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unless otherwise stated.no universal diagnostic criteria for PCOS [4], although
most clinicians and researchers have accepted the definition
published after the consensus conference in Rotterdam in
2003 [5]. Women are diagnosed with PCOS if they have at
least two of the following criteria: a) oligo- or amenorrhoea,
b) hyperandrogenemia or clinical signs of hyperandrogen-
ism, c) sonographically diagnosed polycystic ovaries, after
exclusion of other related disorders.
The pathogenesis of PCOS is a complex mixture of
genetic and environmental origins [4]. Insulin resistance
(IR) and compensatory hyperinsulinemia are observed in
as many as 50%-60% of PCOS women [6]. Moreover,
women with PCOS exhibit a four-fold higher incidence
of metabolic syndrome. The prevalence of metabolicLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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on study design and population [7-9].
Metabolic syndrome has been increasingly diagnosed
in the general population in recent decades. It is defined
as a combination of risk factors for type 2 diabetes melli-
tus (T2DM) and cardiovascular disease (CVD), including
dyslipidemia, hyperglycemia, abdominal obesity, and
hypertension [10], three or more of which are required
for the diagnosis [11]. According to data from the third
National Health and Nutrition Examination Survey
(NHANES III, 1988–1994), the overall prevalence of pa-
tients with manifest metabolic syndrome was 22%, in-
creasing with age and depending on sex and ethnic origin
[12]. If untreated, metabolic syndrome likely results in the
early development of life-threatening sequelae such as
T2DM, CVD and stroke [13-17]. It is not yet clear, how-
ever, to what degree these risk profiles are associated with
cardiovascular outcomes in women with PCOS [18].
Very recently, the human plasma vitamin E-binding pro-
tein afamin was reported to be highly significantly associ-
ated with criteria for metabolic syndrome in three
independent human general populations [19]. In that
work, data from a prospective study design as well as cor-
responding data from afamin-transgenic mice suggest a
role of afamin in the development of metabolic syndrome.
Afamin was discovered in 1994 as the fourth member
of the human albumin gene family, which includes human
serum albumin, alpha-fetoprotein and vitamin D-binding
protein [20]. Afamin is a human plasma glycoprotein of 87
kD with 15% carbohydrate content and 55% amino acid
sequence similarity to albumin. Circulating plasma afamin
is primarily of hepatic origin [20]. Abundant concentra-
tions of afamin have been described in plasma and other
body fluids such as follicular, cerebrospinal and seminal
fluid [21].
We previously demonstrated multiple vitamin E-
binding sites of human afamin using a radio-ligand assay
[22]. Afamin concentrations were found to correlate
with those of vitamin E in follicular and cerebrospinal
fluids, but not in plasma [21]. This may indicate a dis-
sociation of afamin from its vitamin E carrier function in
plasma, unlike its physiological carrier function in fol-
licular and cerebrospinal fluids.
Prompted by these observations, we measured afamin
concentrations in patients with and without PCOS and
investigated the association between afamin, IR and
metabolic syndrome as a first step in establishing afamin




Eligible subjects for this study were recruited from the De-
partment of Gynecologic Endocrinology and ReproductiveMedicine of Innsbruck Medical University. We approached
reproductive-age women, 18–45 years of age, who were be-
ing evaluated at our clinic for irregular menses, hirsutism,
and/or infertility between February and December 2009.
We classified the subjects based on the diagnosis of
PCOS according to the Rotterdam Consensus criteria
[5]. Biochemical hyperandrogenemia was defined as total
testosterone concentration ≥0.4 ng/ml, as validated in
our laboratory. We made further subgroupings based on
the presence of IR defined as a HOMA Index of ≥2.4
[23]. In selected cases, the presence of IR was further
confirmed by a modified three-hour glucose tolerance
test with an AUCinsulin of >12,000 μIU*180 min/mL de-
fined as IR. Metabolic syndrome was defined according
to the NCEP-ATP-III guidelines as the presence of at
least three of five criteria: fasting glucose ≥110 mg/dL,
waist >88 cm, blood pressure ≥130/≥85, triglycerides ≥150
mg/dL, and HDL ≤50 mg/dL [24]. The control group con-
sisted of women in whom PCOS and/or non-classical ad-
renal hyperplasia (NCAH) were excluded. Most of the
patients in the control group were diagnosed with either
male factor infertility or tubal infertility.
Exclusion criteria included a history of endometriosis,
diabetes, thyroid dysfunction or known metabolic disor-
ders, chronic inflammatory conditions, including rheu-
matologic conditions. None of the women included in
this study were taking oral contraceptives, hormonal
medications, or insulin-sensitizing drugs. The study was
approved by the Ethics Committee of Innsbruck Medical
University. All participating subjects provided written in-
formed consent.
Clinical and laboratory data collection
Clinical evaluation of the subjects included menstrual his-
tory and the presence of acne, hirsutism (evaluated with
the Ferriman-Gallwey score) [25], seborrhoea, and andro-
genic alopecia. BMI, waist circumference, hip circumfer-
ence, systolic and diastolic blood pressure as well as the
appearance of the ovaries on ultrasound were recorded.
Subjects underwent a peripheral blood draw after over-
night fasting on cycle day 3–5 following a spontaneous or
progesterone-induced bleed to determine a metabolic
(total cholesterol, LDL cholesterol, HDL cholesterol, tri-
glycerides, fasting glucose, fasting insulin) and hormone
panel (luteinizing hormone (LH), follicle-stimulating hor-
mone (FSH), estradiol (E2), dehydroepiandrosterone sul-
fate (DHEAS), testosterone, sex hormone-binding globulin
(SHBG), free androgen index (FAI), prolactin and thyroid-
stimulating hormone (TSH)). A separate blood sample
collected for measurement of afamin was centrifuged at
low speed, aliquoted and the serum stored at −80°C until
analysis.
In addition, women with suspected PCOS underwent
a 3 h, 75 g load oral glucose tolerance test (OGTT) for
Table 1 Anthropometric characteristics, hormone






mean ± SD or
*median ± IQR.
mean ± SD or
*median ± IQR.
Age yrs 27.70 ± 5.33 32.14 ± 7.39 0.001
BMI kg/m2 28.37 ± 7.14 23.278 ± 4.34 0.001
Waist circumference cm 99.33 ± 13.22 96.00 ± 9.90 0.012
Blood pressure systolic mmHg 124.39 ± 12.78 122.55 ± 12.76 0.532
Blood pressure diastolic mmHg 83.80 ± 12.22 79.74 ± 9.97 0.125
LH U/L* 8.00 ± 5.70 4.35 ± 2.98 0.001
FSH U/L* 5.85 ± 1.63 6.85 ± 3.25 0.037
LH/FSH* 1.51 ± 1.30 0.61 ± 0.37 0.001
E2 ng/L* 49.50 ± 22.25 39.00 ± 28.50 0.060
DHEAS mg/L* 1.94 ± 1.70 1.34 ± 0.95 0.008
Testosterone μg/L* 0.54 ± 0.36 0.22 ± 0.14 0.001
SHBG nmol/L* 35.45 ± 38.18 55.45 ± 35.65 0.003
FAI Index* 5.85 ± 6.14 1.78 ± 1.61 0.001
Fasting glucose mg/dL 87.30 ± 6.94 87.83 ± 8.68 0.734
Fasting insulin U/L* 9,8 ± 10,50 6,65 ± 5,92 0.011
Total cholesterol mg/dL 189.09 ± 33.10 181.43 ± 32.97 0.267
HDL cholesterol mg/dL 57.21 ± 16.79 60.87 ± 15.21 0.274
LDL cholesterol mg/dL 108.00 ± 27.5 96.50 ± 36.25 0.089
Triglycerides mg/dL* 101.00 ± 61.00 81.50 ± 44.75 0.031
AUC Insulin μIU*180 min/mL* 9935 ± 9762
AUC Glucose mg/dl*180 min/mL 18606 ± 2762 16510 ± 1136 0.201
HOMA Index* 2.16 ± 2.37 1.39 ± 1.24 0.013
Afamin mg/L* 66.43 ± 19.60 62.33 ± 18.53 0.745
Values of variables are given as mean ± standard deviation (SD), or *median ±
IQR. Statistically significant p values are shown as bold numbers. AUC: area
under the curve.
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ously described [9]. In all women meeting criteria for
PCOS late onset and heterozygous non-congenital adrenal
hyperplasia were excluded with an ACTH stimulation test
following overnight dexamethasone suppression, as previ-
ously described by Lejeune-Lenain [26].
Laboratory analyses
Hormone concentrations were measured by specific
commercially available immunoassays. Total testoster-
one was determined using a radioimmunoassay (RIA)
method with a Coat-a-count In-vitro Diagnostic Test Kit
(Diagnostic Products Corporation, Los Angeles, CA,
USA) in a Siemens Immulite 2000 Immunoassay system.
The sensitivity of this assay was 0.04 μg/L and the intra-
assay and inter-assay coefficient of variation (CV) for
the range of values pertinent to our patients was less
than 10%. The free androgen index (FAI) was calculated as
follows: total testosterone (nmol/L) × 100/SHBG (nmol/L).
Afamin serum concentrations were quantified in dupli-
cate by custom-made sandwich-type ELISA using specific
mono- and polyclonal antibodies recognizing human afa-
min (MicroCoat Biotechnologie, Bernried, Germany), as
previously described [21,22,27]. Within-run and total CV
were 3.3% and 6.2%, respectively, at a mean concentration
of 73 mg/L [27].
The lipid profile including cholesterol and triglycerides
as well as fasting glucose and insulin were determined
using routine automated laboratory methods. Glucose
was measured with the GOD-PAP method (glucose oxi-
dase) and Roche/Hitachi 917 with an intra-assay CV of
0.9% and an inter-assay CV of 1.9%. Insulin was determined
by electrochemiluminescence immunoassay (ECLIA) with
an intra-assay CV of 1.9% and an inter-assay CV of 2.6%.
Statistical analyses
Baseline characteristics of the two groups were compared
using T test, chi-square, and Fisher’s exact test, where ap-
propriate. Median concentrations of afamin were com-
pared between groups using non-parametric tests, the
Mann–Whitney test for two-group comparisons, and the
Kruskal-Wallis test for multi-group comparisons. Bivariate
relations between afamin and covariates were analyzed
with Spearman’s Rank Correlation Coefficient, and linear
regression was used to test which variables were inde-
pendent predictors of afamin level. The pre-selected inde-
pendent variables evaluated were BMI, fasting insulin,
HOMA Index, triglycerides, and LDL cholesterol. Statis-
tical analyses were performed with GraphPad Prism, Ver-
sion 6.01 (GraphPad Software, San Diego, CA, USA), and
SPSS 22 (SPSS, Inc., Chicago, IL, USA).
G*Power 3.1.2 (Kiel, Germany) was used to calculate
the sample size needed for this study. Using our previ-
ously published normal population median of serumafamin of 64 mg/L [27] and setting an α error probabil-
ity of 0.05 and power (1-β error probability) of 0.80, we
performed a two-tailed sample size calculation to detect
a difference of 12% between non-PCOS and PCOS sub-
jects. A minimum of 90 subjects was needed to achieve
adequate power to detect this difference.Results
We recruited 102 women for this study, 53 with PCOS
and 49 without PCOS. Baseline characteristics, hormone
concentrations and metabolic profiles of the study sub-
jects are presented in Table 1. Women with PCOS were
younger, had a higher BMI and waist circumference, and
were more likely to have cycle irregularities, seborrhoea,
and hirsutism. As expected, women with PCOS had
higher concentrations of LH and testosterone, a higher
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than did non-PCOS women.
Women with PCOS had significantly higher mean fast-
ing insulin and triglyceride concentrations and a higher
mean HOMA Index and were more likely to have IR
(45.3% vs. 21.4%, p = 0.015), but not more likely to meet
the criteria for MetS (20.75% vs. 8.11%, p = 0.103) than
were those without PCOS.
Median afamin concentration was 66.43+/−19.60 mg/L
in the PCOS and 62.33+/−18.53 mg/L in the non-PCOS
group, a statistically non-significant difference (p = 0.745,
Table 1). Further separation of the subjects according to
the presence of IR revealed a significant difference in afa-
min concentrations between the four groups (H(3) =
13.415, p = 0.004; Figure 1). Using Dunn’s multiple com-
parison test, we found significantly higher median afamin
levels in PCOS with IR as compared to PCOS without
IR and controls without IR, namely: PCOS with IR:
73.06+/−27.36 mg/L, PCOS without IR: 64.25+/−17.41
mg/L, controls without IR: 60.44+/−21.03 mg/L, p = 0.033
and p = 0.011. However, no difference in afamin levels
was seen when comparing controls with IR and controls
without IR (76.20+/−27.96 mg/L and 60.44+/−21.03 mg/L
p = 0.235).
We further conducted a one-way analysis of covari-
ance (ANCOVA) using afamin as the dependent vari-
able, PCOS as the independent variable (two levels) and
fasting insulin as the covariate. ANCOVA (between-sub-
jects factor: PCOS, control) showed no main effects of
























Figure 1 Afamin concentrations in PCOS patients and non-PCOS
controls classified according to insulin resistance. Median serum
afamin concentrations in PCOS patients and non-PCOS controls with
or without IR. Subjects were subgrouped into PCOS patients with
(n = 24) or without IR (n = 29) and into non-PCOS controls with (n = 9)
or without IR (n = 33). Afamin concentrations were evaluated group-
wise with the Kruskal-Wallis H test using Dunn’s correction for multiple
comparisons. * indicates significance at the p < 0.05 level.the insulin concentration that mainly determines afamin
value F(1.92) = 10.06, p = 0.002, ηp2 = 0.10. When con-
trolling for fasting insulin, the adjusted means for afamin
were 70.42 mg/L (SE = 2.77) and 69.14 mg/L (SE = 2.45)
for the PCOS and the control group, respectively.
On individual correlations using the Spearman coeffi-
cient r, the following parameters correlated significantly
with afamin concentrations: BMI (r = 0.231, p = 0.02),
waist/hip ratio (r = 0.310, p = 0.019), fasting insulin (r =
0.313, p = 0.002), LDL cholesterol (r = 0.257, p = 0.013),
HOMA Index (r = 0.310, p = 0.002), and triglycerides (r =
0.372, p = 0.001) as the only criterion of metabolic
syndrome. No statistically significant correlation was seen
between afamin and other parameters of metabolic syn-
drome, including waist circumference (r = 0.259, p =
0.052), systolic or diastolic blood pressure (r = 0.194,
p = 0.085; r = 0.199, p = 0.077), fasting glucose (r = 0.055,
p = 0.582) or HDL (r = −0.166, p = 0.111).
Afamin correlated with FAI (r = 387, p = 0.0001) but not
with testosterone (r = 0.015, p = 0.879), SHBG (r = −0.134,
p = 0.182), FSH (r = −0.156, p = 0.120) or E2 (r = −0.147,
p = 0.145).
However, on multivariable linear regression including
as independent variables selected parameters that sig-
nificantly correlated with afamin (BMI, LDL cholesterol,
triglycerides, HOMA Index and fasting insulin) only tri-
glyceride concentration was seen to be an independent
predictor of afamin concentration (β coefficient = 0.271,
p = 0.019, Durbin-Watson 1.468).
Finally, we compared median afamin concentrations
between those with and without diagnosed metabolic
syndrome, independent of the presence of PCOS. We
found markedly elevated afamin concentrations in
women with metabolic syndrome versus without, values
that were more than 12 mg/L higher than in women
without metabolic syndrome, as shown in Figure 2
(77.43+/−28.60 mg/L and 65.08+/−18.03 mg/L, respect-
ively, (p = 0.010)).
Discussion
Women with PCOS have a higher prevalence of several
risk factors for CVD, including dyslipidemia, IR, type 2
diabetes and hypertension, than do age-matched, non-
PCOS women [28]. Although these risk factors are exac-
erbated by the concomitant obesity seen in some PCOS
women, they are also present in lean, non-obese women
with PCOS, many of whom exhibit IR [9,29,30]. Due to
the elevated lifetime risk of developing metabolic syn-
drome and its subsequent atherosclerosis and CVD
complications, the Androgen Excess and Polycystic
Ovary Syndrome (AE-PCOS) Society has published spe-
cific recommendations for screening and management
of women with PCOS [31]. Early identification of























Figure 2 Afamin concentrations and metabolic syndrome.
Serum afamin concentrations in all investigated subjects, independent
of the presence of PCOS, but subgrouped into patients without
(n = 76) or with (n = 14) metabolic syndrome. ** indicates significance
at the p < 0.01 level.
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and/or cholesterol-lowering drugs may be initiated for
primary CVD prevention.
The present study found no difference in serum con-
centrations of afamin, a vitamin E-binding protein, be-
tween women with PCOS and non-PCOS controls.
When sub-grouping all investigated subjects according
to the presence of IR, however, women with IR exhibited
higher afamin concentrations, regardless of the presence
of PCOS. A one-way analysis of covariance showed that
it is fasting insulin and not the diagnosis of PCOS that
correlates with afamin. Afamin was markedly higher in
women already diagnosed with metabolic syndrome. These
findings corroborate those of a previous population-based
study that likewise showed that afamin concentrations
were associated with the number of metabolic syndrome
criteria in groups of men and women with mean age be-
tween 50 and 60 [19]. Despite evaluating a much younger
cohort of women with an average age of around 30, the
present study nonetheless found afamin levels to be simi-
larly elevated. Age has, however, no or very little influence
on afamin concentrations, as shown in a group of blood
donors with different age subgroups [27]. Thus, our find-
ings confirm that young women with PCOS are more
likely to have metabolic syndrome, and afamin might serve
as a discriminatory predictive parameter of IR in young
PCOS patients. As such, PCOS can be considered a con-
founder in the relationship between afamin and IR.
This study confirms and extends a recently published
independent investigation of afamin in PCOS patients
[32]. The two studies differ, however, in study design
and investigated key parameters. While Köninger et al.
analysed retrospective data in a cross-sectional study,
our patients were prospectively recruited. Furthermore,we were able to analyse the prevalence of IR based on
HOMA Index as well as the prevalence of metabolic
syndrome in both the PCOS- and the non-PCOS groups
and provide information on the diagnosis of metabolic
syndrome. In this way it was shown that, similar to the
general population [19], afamin concentrations are asso-
ciated with the prevalence of metabolic syndrome in
PCOS patients. The present study did not find women
with PCOS to have higher afamin levels than controls,
as reported by Köninger et al. The differing results
might be partially explained by the lack of prevalence
data on IR and metabolic syndrome for the control
group in the Köninger study, which could greatly influence
the results if the control group consisted of a population
almost exclusively having normal insulin sensitivity. Stud-
ies including larger numbers of subjects with documented
IR levels and metabolic syndrome will therefore be neces-
sary in future for final confirmation.
Of the laboratory parameters for metabolic syndrome
evaluated, triglyceride level was the sole independent
predictor of afamin concentrations. Interestingly, Dokras
et al. reported that an elevated serum triglyceride/HDL
cholesterol ratio was highly sensitive and specific for the
detection of metabolic syndrome in women with PCOS
[33]. The study by Kronenberg et al. [19] likewise found
that afamin most strongly correlated with triglycerides
and waist circumference in older populations of women
and men.
Kronenberg et al. followed their subjects prospectively
for five years and were able to show that each incremen-
tal increase in afamin of 10 mg/L increased the probabil-
ity of being diagnosed with metabolic syndrome by 74%.
Unfortunately, at this time we have no longitudinal data
available for the women in the present cohort, but we
are likewise following up the women in this study and
re-evaluating afamin concentrations and components of
metabolic syndrome in the hope that afamin may be
useful as a predictive parameter for the development of
metabolic syndrome in younger women with insulin
resistance.
Conclusions
It is only in recent years that more attention has been
paid to the metabolic abnormalities of PCOS, and not
just the syndrome’s implications for infertility and infer-
tility treatment. As discussed in a recent review by Bates
and Legro [34], understanding the true health implica-
tions of PCOS is difficult due to the heterogeneous na-
ture of the condition and the lack of long-term cohort
studies. Thus, large prospective longitudinal studies,
ideally involving many ethnic groups, are needed to im-
prove our understanding of the long-term health risks
associated with PCOS. The results of the study at hand
show that elevated afamin concentrations are associated
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women and may potentially serve as an independent
predictor for the development of metabolic syndrome in
at-risk women, especially those with insulin resistance.
For this purpose, however, prospective studies with suffi-
ciently large cohorts of well-characterised PCOS women
will have to be performed.
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